Molecular diagnostics firm Nanosphere believes the results of a new multicenter study that assessed the performance of its Verigene Gram-Positive Blood Culture Test could lead to broader clinical adoption, according to a company spokesperson.

Lindsay Saxon told BioArray News this week that the results of the study, published recently in the journal PloS Medicine, are "significant" as they "further validate the compelling value" of the test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.